<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285050</url>
  </required_header>
  <id_info>
    <org_study_id>NA00040361</org_study_id>
    <secondary_id>R01DA013806</secondary_id>
    <nct_id>NCT01285050</nct_id>
  </id_info>
  <brief_title>Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds</brief_title>
  <official_title>Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The chief purpose of this research is to evaluate interferon alpha sensitivity and cell type
      specific levels of interferon receptor and interferon stimulated genes and proteins in HIV/
      HCV (hepatitis C virus) coinfected persons before and after administration of HIV medications
      (antiretroviral therapy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to perform liver biopsy by microlaparoscopy on previously untreated HIV/HCV
      coinfected persons, then give them a dose of peginterferon alfa 2b. HCV and HIV kinetics will
      be studied. Afterward, HIV will be treated using antiretroviral therapy and the procedure
      will be repeated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV RNA</measure>
    <time_frame>48 hours after interferon administration</time_frame>
    <description>HCV RNA determined by reverse transcription polymerase chain reaction and measured as log IU/ml 48 hours after a single dose of peginterferon alfa 2b 1.5 μg/kg.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV Infection</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>pre post ART</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HCV and HIV viral load pre and post antiretroviral therapy (ART). ART is the intervention and the comparison is the HIV and HCV viral load reductions as determined by RT-PCR after administration of interferon alfa in each instance (before and after ART)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral therapy (ART)</intervention_name>
    <description>Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.</description>
    <arm_group_label>pre post ART</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>raltegravir is an HIV medication given 400 mg twice daily by mouth</description>
    <arm_group_label>pre post ART</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine and tenofovir disoproxil fumarate</intervention_name>
    <description>Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth</description>
    <arm_group_label>pre post ART</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Human

          -  Able to provide written informed consent

          -  HIV antibody positive

          -  HIV viral load positive

          -  HIV treatment naive

          -  Hepatitis C antibody positive

          -  Hepatitis C viral load positive

          -  Hepatitis C treatment naive

          -  Approved to take HIV medications for minimum 9 months

          -  Willing to use contraception, Life expectancy greater than 2 years

        Exclusion Criteria:

          -  Significant opportunistic infections within 12 month

          -  Hepatitis B positive

          -  Evidence of liver cirrhosis

          -  Decompensated liver disease

          -  Chronic alcohol abuse

          -  Allergy to raltegravir, tenofovir, and/or emtricitabine

          -  Active or suspected malignancy

          -  Sarcoidosis

          -  Active TB

          -  Coronary artery disease

          -  Uncontrolled seizures

          -  Untreated thyroid disease

          -  Untreated diabetes

          -  Weight greater than 125 kg

          -  Severe depression or severe psychiatric disorder

          -  Ongoing alcohol or illicit drug use

          -  Pregnant, nursing, pr planning to become pregnant

          -  Allergy to interferon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <results_first_submitted>August 15, 2016</results_first_submitted>
  <results_first_submitted_qc>October 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2016</results_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>David Thomas</investigator_full_name>
    <investigator_title>Chief, Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Human immunodeficiency virus</keyword>
  <keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
  <keyword>AIDS Virus</keyword>
  <keyword>Immunodeficiency Virus, Human</keyword>
  <keyword>Virus, Human Immunodeficiency</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C, chronic</keyword>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Hepatitis C antibodies</keyword>
  <keyword>Hepatitis C antigens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pre Post ART</title>
          <description>HCV and HIV viral load pre and post antiretroviral therapy
Anti-HIV Agents: Interferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications.
raltegravir: HIV medication, 400 mg twice daily by mouth
Emtricitabine and tenofovir disoproxil fumarate: HIV medication, combination pill, once per day by mouth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre Post ART</title>
          <description>HCV and HIV viral load pre and post antiretroviral therapy
Anti-HIV Agents: Interferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications.
raltegravir: HIV medication, 400 mg twice daily by mouth
Emtricitabine and tenofovir disoproxil fumarate: HIV medication, combination pill, once per day by mouth</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV infected</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HCV RNA</title>
        <description>HCV RNA determined by reverse transcription polymerase chain reaction and measured as log IU/ml 48 hours after a single dose of peginterferon alfa 2b 1.5 μg/kg.</description>
        <time_frame>48 hours after interferon administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre ART HCV RNA Decline</title>
            <description>HCV viral load determined by RT-PCR and reported as log IU/ml before giving antiretroviral therapy (ART)
Interferon alfa-2b was administered once as part of a pharmacokinetic study before and after ART.
ART included:
raltegravir: HIV medication, 400 mg twice daily by mouth
Emtricitabine and tenofovir disoproxil fumarate: HIV medication, combination pill, once per day by mouth</description>
          </group>
          <group group_id="O2">
            <title>Post ART HCV Decline</title>
            <description>HCV RNA determined by RT-PCR and expressed as log IU/ml after ART</description>
          </group>
        </group_list>
        <measure>
          <title>HCV RNA</title>
          <description>HCV RNA determined by reverse transcription polymerase chain reaction and measured as log IU/ml 48 hours after a single dose of peginterferon alfa 2b 1.5 μg/kg.</description>
          <units>log IU/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.17" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0.81" lower_limit="0.34" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pre Post ART</title>
          <description>HCV and HIV viral load pre and post antiretroviral therapy
Anti-HIV Agents: Interferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications.
raltegravir: HIV medication, 400 mg twice daily by mouth
Emtricitabine and tenofovir disoproxil fumarate: HIV medication, combination pill, once per day by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>bleeding</sub_title>
                <description>As an expected potential complication of liver biopsy, one patient had bleeding that required observation in the hospital. No residual complications were noted.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Thomas</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-502-6043</phone>
      <email>dthomas@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

